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We constructed a patient-based interval scale using Rasch analysis, speciﬁcally suited to quantify the eﬀects of Pompe disease on
patient’s ability to carry out daily life activities and their social participation: Rasch-built Pompe-speciﬁc Activity scale. Between July
2005 and April 2011, 186 patients aged 16 or older, participated to develop this scale. External construct validity was determined
through correlations with the MRC sumscore and Rotterdam Handicap Scale. Furthermore, test–retest reliability was determined in
a subgroup of 44 patients. Finally, individual person-level responsiveness was used to determine the proportion of patients
demonstrating signiﬁcant improvement or deterioration during their natural disease course, or during treatment with enzyme
replacement therapy. Of the original 49 items, 31 were removed after investigation of model ﬁt, internal reliability, threshold
examination, item bias, and local dependency. The remaining 18 items were ordered on a linearly weighted scale and demonstrated
good discriminative ability (Person Separation Index 0.96), external construct validity (intraclass correlation coeﬃcient (ICC) for
MRC sumscore 0.82, and for the Rotterdam handicap scale 0.86), reliability of person’s location (ability comparison: ICC 0.95), and
responsiveness. We therefore conclude that the R-PAct scale enables us to accurately detect limitations in activities and social
participation throughout the entire disease spectrum in patients with Pompe disease.
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Pompe disease – also named glycogen storage disease
type II – is an inherited metabolic disorder in which partial
or total absence of the enzyme acid a-glucosidase causes
intra-lysosomal accumulation of glycogen in many tissues
[1]. The clinical spectrum ranges from the rapidly progres-
sive classic infantile phenotype, which – when not treated
with enzyme replacement therapy – leads to death within0960-8966 2012 Elsevier B.V.
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Open access under the Elsevier OA license.the ﬁrst year of life [2,3], to a more slowly progressive phe-
notype that primarily aﬀects skeletal and respiratory mus-
cles [4–6]. Progressive muscle weakness eventually leads to
wheelchair and ventilator dependency in a substantial
amount of patients.
As a consequence, Pompe disease strongly aﬀects
patients’ ability to carry out daily life activities and inﬂu-
ences their social participation. Quantifying these aspects
is important for the management of individual patients
and for evaluating eﬀects of enzyme replacement therapy
(ERT) [7,8] or future treatment modalities. At present, lim-
itations in activities and social participation are often
assessed by non-speciﬁc functional tests such as the
10-metre walk test and the six-minute walk test [7,8], or
ordinal measurement scales such as the Rotterdam
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It is now realised that these ordinal scales are prone to dif-
ferential sensitivity – meaning that a one-point change in
score at the centre of the scale may not be the same as a
one-point change at the extremes [12,13]. Therefore, for
health evaluation, a modern scientiﬁc approach transform-
ing ordinal scores into a linearly weighted measure is
required.
We thus developed a patient-based interval scale (Ras-
ch-built Pompe-speciﬁc Activity scale: R-PAct scale) using
Rasch analysis [14,15]. Subsequently, we evaluated its
validity, reliability and responsiveness. It is to be expected
that this measurement scale, based on patients’ experiences
of limitations in daily life, will have a high discriminatory
capacity and will be able to measure changes in functional
status, which aids in follow-up of the natural disease course
or in the evaluation of therapeutic eﬃcacy throughout the
entire spectrum of disease severity.
2. Patients and methods
2.1. Study population and procedures
Between July 2005 and April 2011, 186 patients aged 16
or older, participated to develop the R-PAct scale. Patients
were recruited though patient organisations aﬃliated with
the International Pompe Association (IPA) in Canada,
the Netherlands, the United Kingdom, and the United
States [6]. In addition, patients were recruited through neu-
romuscular centres in the Netherlands and Belgium. Forty–
four of the Dutch patients completed the scale a second
time 2–4 weeks later for test–retest reliability studies. To
evaluate responsiveness of the R-PAct scale, patients were
followed longitudinally up to 36 months during the natural
disease course or during treatment with enzyme replace-
ment therapy. Patients from the international patient
cohort completed the scale every year, while the Dutch
and Belgian patients completed the scale every 3–6 months.
The studies were approved by the Medical Ethics Commit-
tee of Erasmus MC University Medical Center. All patients
gave written informed consent.
2.2. Scale development
2.2.1. Preliminary R-PAct questionnaire
A preliminary R-PAct questionnaire was developed tak-
ing the following steps:
(1) To cover the widest range of physical functioning,
activities, and participation skills important for
patients with Pompe disease, data from an interna-
tional patient survey among 263 patients with Pompe
disease were used as the basis for construction of the
current questionnaire [6]. In this survey, patients pro-
vided information about their disease history and
current status by means of self-reported question-
naires. Firstly, an inventory was made of the answerson the following open question from this patient sur-
vey: “what are your most important (limiting, annoy-
ing) problems?” Secondly, answers to the question
“can you describe your walking problems?” were
used to reﬁne the items on walking. Thirdly, patients
were asked to indicate other items that were impor-
tant for their daily life but that were not discussed
in the questionnaires.
(2) Additional items based on the Rotterdam Handicap
Scale (1 item) [10] and paediatric evaluation of dis-
ability inventory (8 items) [16], thought to be of
importance by expert judgement, were included.
(3) This preliminary list comprising 136 items was classi-
ﬁed according to the International classiﬁcation of
functioning, disability and health (ICF) into the
domains impairment, activities, and participation
[17].
(4) A panel of experts consisting of senior staﬀ members
from our departments of neurology, paediatrics,
internal medicine, and clinical genetics, all involved
in research projects and treatment of Pompe disease,
discussed the items and their classiﬁcation. Changes
were implemented according to their suggestions:
items that were almost identical were merged, and
items that were mentioned only occasionally were left
out. After reaching consensus, a list of 49 activity and
participation items was selected for the purpose of the
current study. All items had ﬁve response options: (0)
unable to perform; (1) able to perform, but with great
diﬃculty; (2) able to perform, but with some diﬃ-
culty; (3) able to perform, but with little diﬃculty;
(4) easy to perform, without diﬃculty; or ‘not
applicable’.
(5) The questionnaire was tested in a group of ten
healthy subjects. Based on their comments, changes
were made to prevent overlap and to improve clarity.
(6) For use in English speaking patient groups, this ﬁnal
questionnaire was translated and back-translated by
two independent certiﬁed translators according to
published guidelines [18].
The items of the preliminary R-PAct questionnaire are
listed in Webappendix 1.
2.3. Final R-PAct scale
2.3.1. Rasch analysis
Since a sample size of approximately 250 is needed to
adequately estimate item diﬃculty [26], we decided to stack
the data of the ﬁrst (n = 186) and second (n = 44) assess-
ments, controlling for ‘time factor’ as possible confounding
factor [27], leading to a total number of 230 records to be
examined. In the model construction, items scored as ‘not
applicable’ were interpreted as missing data. Items with
more than 10% missing values and questionnaires with
more than 10% unanswered items were omitted as a quality
control procedure. Thereafter, the remaining response
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ch unidimensional measurement models (RUMM 2030)
[19]. Through Rasch analysis, ordinal scores are trans-
formed into interval measures, placing both item and per-
son parameter estimates on the same log-odds units
(logit) scale, which allows for linear transformation of the
raw scores [14,15]. A detailed description of the statistical
modelling procedures has been provided elsewhere, also
speciﬁcally for neurologists [20–22]. Brieﬂy, the following
Rasch model requirements were checked:
(A) Fit statistics and ﬁt residuals: To test whether the data
meet the model expectations, three overall ﬁt statis-
tics were considered. Two are item–person interaction
statistics, expressed as z-scores: if the items and per-
sons ﬁt the model, a mean around zero and a stan-
dard deviation of 1 would be expected. The third is
an item–trait interaction statistic, reported as chi-
square (v2): a non-signiﬁcant chi-square reﬂects the
required property of invariance. Additionally, indi-
vidual person-ﬁt statistics and item-ﬁt statistics were
examined as residuals, and by using a chi-squared
statistic. Residuals between ±2.5 are considered ade-
quate ﬁt to the model, whilst a signiﬁcant v2 points to
misﬁt.
(B) Internal reliability: This was measured by the Person
Separation Index (PSI). A value of P0.7 indicates
that the scale is able to diﬀerentiate at least two
groups of patients, and is generally considered to be
acceptable [23].
(C) Threshold examination: The point between two adja-
cent response categories where both responses are
equally probable is called the “threshold”. Diﬃculty
to discriminate between response options – for exam-
ple due to too many possibilities – may lead to disor-
dered thresholds. The overall model ﬁt may improve
by merging of categories.
(D) Item bias: This was assessed by means of diﬀerential
item functioning (DIF) [24]. DIF occurs when the
probability of responding to an item is systematically
diﬀerent between groups with equal levels of disabil-
ity but diﬀerences in another characteristic (e.g.
age). This was examined by analysis-of-variance for
the following arbitrarily chosen personal factors,
aiming for an equal distribution of patients among
the categories: (1) age (<40 years, 40–50 years, 50–
60 years, or P60 years); (2) gender (male or female);
(3) duration of symptoms (<5 years, 5–10 years, 10–
20 years, or P20 years); (4) country of assessment
(Belgium, Canada, the Netherlands, UK, or USA);
and (5) language (Dutch or English).
(E) Local dependency: Local dependency arises when
items are linked. For example, a patient who is
unable to walk 100 m, will also be unable to walk
1 km. An inter-item residual correlations P0.3 indi-
cates local dependency [25].(F) Unidimensionality: This was tested by a principal
component analysis of the residuals, needed to sup-
port the assumption of local independence and, con-
sequently, the unidimensionality of the scale [21].
Throughout the analyses, we continuously monitored
whether Rasch model criteria were met: items that did
not fulﬁll these requirements were removed, or adjusted
to ﬁt the model, while monitoring changes and ﬁt statistics
of the individual remaining items and the overall model ﬁt.
As a last step, the calculated Rasch person locations (in
logits) were transformed into a more understandable cen-
tile metric ranging from 0 (most severe activity and partic-
ipation restrictions) to 100 (no activity limitations and
participation restrictions).
2.3.2. Validity
The external construct validity was assessed by correla-
tions between the ﬁnal R-PAct scale and the Medical
Research Council (MRC) [28] sumscore and Rotterdam
Handicap Scale (RHS) [10]. To obtain the most appropri-
ate graphical model ﬁt, regression analysis with restricted
cubic spline functions was performed on the summed raw
R-PAct scores: the intraclass correlation coeﬃcient (ICC)
is reported [29].
2.3.3. Medical Research Council (MRC) score
Through manual muscle testing using the MRC grading
system [28], we assessed the degree of skeletal muscle weak-
ness in the 88 patients participating in the ongoing study on
the natural course of Pompe disease in the Netherlands.
Since, in patients with Pompe disease, muscle weakness is
present predominantly in the proximal muscle groups
(‘limb-girdle’ weakness), leaving the distal muscle groups
relatively unaﬀected until the late stages of the disease, a
sumscore was calculated for the following muscles or mus-
cle groups: neck extensors, neck ﬂexors, and bilateral
shoulder abductors, elbow ﬂexors, elbow extensors, hip
ﬂexors, hip abductors, knee ﬂexors and knee extensors
(range 0 (paralytic)–80 (normal strength)).
2.3.4. Rotterdam Handicap Scale (RHS)
The RHS was developed originally for measuring hand-
icap in patients with immune-mediated polyneuropathies
[10], and was proven to be useful for examining limitations
in activities and participation in patients with Pompe dis-
ease [9]. The scale consists of nine questions on the topics
of mobility indoors and outdoors, kitchen tasks, domestic
tasks indoors and outdoors, leisure activities indoors and
outdoors, travelling, and work/study. The total score
ranges from 9 to 36, with higher values representing a
lower level of handicap.
2.3.5. Reliability
To investigate whether the hierarchy of patients’ ability
location was consistent over time, test–retest reliability
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calculating the intraclass correlation coeﬃcient using a
one-way random eﬀects analysis-of-variance (ANOVA)
model for group comparison.
2.3.6. Responsiveness
Responsiveness was calculated at the individual person-
level, since modern clinimetric methods have demonstrated
that the standard error (SE) around an individual patients’
ability level, and therewith the clinical importance of
changes within a patient over time, may vary across the
range of an outcome measure [31,32]. As a measure for
individual responsiveness, the minimal clinically important
diﬀerence-standard error (MCID-SE: individual change/
standard error of diﬀerence (SEdiﬀ)) was calculated for
every participating patient at each assessment [33]. To
obtain individual SEs, all data were subjected to the
RUMM 2030 model ﬁrst, hereby creating the location of
each patient (in logits) with the corresponding SE (also in
logits). The cut-oﬀ value for a clinically important change
– improvement or deterioration – was deﬁned at
±1.96  SE. Subsequently, Kaplan–Meier curves were
applied to estimate the cumulative proportion of patients
demonstrating signiﬁcant improvement or signiﬁcant dete-
rioration over time (3, 6, 9, 12,. . . up to 36 months), strat-
iﬁed for ‘treatment’ (natural disease course against enzyme
replacement therapy). The log-rank test was used to exam-
ine possible group diﬀerences.
2.4. Statistics and software
Rasch analyses were performed with the partial credit
model as default (RUMM2030) [19]. Further analyses were
undertaken using Stata Statistical Software for Windows
XP (version 11.0, StataCorp, Texas, USA). Throughout
the analyses, Bonferroni corrections were applied to adjust
the p-values for multiple testing [34].
3. Results
3.1. Study population
The study population comprised patients from the
Netherlands (n = 94), the USA (n = 65), the UK (n = 18),
Canada (n = 6), and Belgium (n = 3). Fifty-one percent
was female. The median age at which patients had been
diagnosed was 37 years (range 1–67 years). Median age atTable 1
Summary statistics of Rasch analysis during construction of the R-PAct scale
Analysis Item ﬁt residuals Person ﬁt residuals
Mean SD Mean SD
Initiala (preliminary R-PAct) 0.254 1.780 0.146 0.982
Final (R-PAct) 0.353 0.826 0.318 0.839
Abbreviations: v2, Chi square; DF, degrees of freedom; SD, standard deviatio
a Thirty-one items were removed from the original preliminary R-PAct quest
all Rasch model expectations.ﬁrst investigation was 50 years (range 23–85 years), and
median disease duration 11 years (range 0–33 years).
Thirty-seven percent of patients were fully ambulatory,
16% used walking devices, and 47% of all patients was
either partially or permanently wheelchair dependent.
Forty-ﬁve percent of patients used mechanical ventilatory
support. Patients from the United States, United Kingdom
or Canada had a longer disease duration (p < 0.01) and
were more frequently ventilator dependent than the Dutch
or Belgian patients (p < 0.01).
3.2. Rasch analysis
3.2.1. Initial analysis on the preliminary R-PAct
questionnaire
The preliminary R-PAct questionnaire (see Appendix 1
for full list of items) did not meet all Rasch model expecta-
tions (Table 1, initial analysis).
3.2.2. Data handling to ﬁt the Rasch model
(1) Thirty items of the preliminary R-PAct questionnaire
demonstrated disordered thresholds, particularly in
the mid-response area (response options 1–3,
Fig. 1). The remaining 19 items had thresholds very
adjacent to each other in the mid-response area.
Based on these observations, we decided to rescore
all items into three response categories as follows:
(0) = (0) unable to perform; (1–3) = (1) able to per-
form, but with diﬃculty; and (4) = (2) able to per-
form without diﬃculty.
(2) Inspection of individual item-ﬁt and individual per-
son-ﬁt statistics showed that 14 items demonstrated
misﬁt to the model, 13 having a signiﬁcant chi-square
probability, and one having ﬁt residuals exceeding
2.5. These items were removed one by one,
continuously checking the class intervals, statistical
control panel and possible changes on other Rasch
requirements.
(3) Thirteen items showed item-bias: six items with
regard to the personal factor ‘country’, three for ‘lan-
guage’, two for ‘age’, and two for ‘duration of symp-
toms’. These items were removed from the analyses.
(4) To identify possible local dependency, all pairs of
items with correlations above 0.28 were evaluated,
starting with the highest correlations. Of each item-
pair, the item showing the least clinical relevancefor Pompe patients.
Item-trait v2 interaction PSI Unidimensionality t-tests (95% CI)
DF p-Value
147 <0.0001 0.98 0.22 (0.187–0.243)
54 0.82 0.96 0.061 (0.032–0.090)
n; CI, conﬁdence interval; PSI, Person Separation Index.
ionnaire. The remaining 18 items as part of the ﬁnal R-PAct scale fulﬁlled
Ideal category probability curve after rescoring of items
Fig. 1. Upper panels: two items (left: prepare a meal, right: walk 1 km) are presented as examples of reversed thresholds. Response categories, particularly
in the mid response area (from 1 to 3) were not equally probable, indicating the inability of the patients to discriminate between these response options.
Thirty of the initial items demonstrated this pattern. Lower panels: ideal probability curves after rescoring the items from 5 to 3 response options.
Are you able to Location SE 
1 comb your hair? -4.533 0.186 
2 eat? -3.943 0.175 
3 put on your trousers? -2.878 0.172 
4 prepare a meal? -2.246 0.166 
5 take a shower? -2.131 0.155 
6 grab an object above the head -1.963 0.166 
7 negotiate obstacles when walking? -0.568 0.180 
8 turn around in bed? -0.453 0.200 
9 walk on uneven ground? 0.001 0.167 
10 stand up from a sitting position 0.536 0.185 
11 walk 1 km outside? 0.653 0.153 
12 walk 1 flight of stairs? 1.165 0.178 
13 bend over and pick up object from the floor? 1.506 0.173 
14 walk at a rapid speed 2.275 0.171 
15 perform garden tasks? 2.415 0.188 
16 practice a sport? 2.465 0.203 
17 squat down and up? 3.164 0.181 
18 run? 4.443 0.254 
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Fig. 2. Threshold distribution map and ﬁt statistics for the 18-item ﬁnal R-PAct scale, fulﬁlling all Rasch model expectations. Items are ordered by
increasing diﬃculty. The easiest item turned out to be ‘are you able to comb hair’, the most diﬃcult one ‘are you able to run’. Red sections (0) = unable to
perform, orange sections (1) = able to perform, but with diﬃculty, green sections (2) = able to perform, without diﬃculty.
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Table 2
Nomogram allowing translation of summed raw scores of the ﬁnal 18-
items R-PAct scale (range 0–36) to an estimate of the Rasch person
location (in logits) and a convenient centile metric (range 0–100). The
corresponding logits in relation to the summed raw scores are provided by
the RUMM software.
R-PAct summed raw
scorea
Rasch person location
(logit)
Centile
metric
0 8.33 0
1 7.25 7
2 6.37 12
3 5.66 17
4 5.05 20
5 4.53 24
6 4.07 26
7 3.65 29
8 3.25 32
9 2.88 34
10 2.52 36
11 2.18 38
12 1.85 40
13 1.54 42
14 1.23 44
15 0.92 46
16 0.61 48
17 0.31 50
18 0.00 52
19 0.31 54
20 0.63 56
21 0.95 58
22 1.29 60
23 1.63 62
24 1.99 64
25 2.34 66
26 2.69 68
27 3.04 70
28 3.40 73
29 3.76 75
30 4.14 77
31 4.55 80
32 5.00 83
33 5.50 86
34 6.09 89
35 6.84 94
36 7.79 100
a The nomogram can only be used when all questions have been com-
pleted by the patient.
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Fig. 3. Correlation between the R-PAct scale summed raw scores and
MRC sumscore (A) and Rotterdam Handicap Scale (RHS) (B). ICC:
intraclass correlation coeﬃcient.
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over-discrimination or under-discrimination on its
category probability curve was removed. In this
way, four items were removed.
After completing these procedures, the ﬁnal R-PAct
scale, comprising 18 items, met all Rasch model expecta-
tions (Table 1, ﬁnal analysis). In the ﬁnal R-PAct scale,
the item ‘are you able to comb your hair?’ was the easiest
to perform whereas the item ‘are you able to run?’ turned
out to be the most diﬃcult task. Item diﬃculty ranged from
4.53 to 4.44 logits and patient ability level from 8.33 to
7.79 logits. Fig. 2 shows the threshold distribution map and
the ﬁt statistics for the 18 items of the ﬁnal R-PAct scale.Table 2 provides a nomogram allowing the translation of
the R-PAct summed raw scores to the calculated Rasch
person location (in logits), and to an understandable centile
metric. Fourteen patients (6%) could not perform any task
at all (ﬂoor eﬀect), and 1 patient (0.4%) was able to per-
form all activities without any diﬃculty (ceiling eﬀect).
3.2.3. External construct validity
The R-PAct scale demonstrated strong correlations with
the MRC sumscore (ICC 0.82) and RHS (ICC 0.86),
reﬂecting good construct validity (Fig. 3). The discrimina-
tory capacity of the R-PAct scale is clearly illustrated in
Fig. 4. Patients with more disability, measured by the use
of walking devices or wheelchair use, scored signiﬁcantly
lower on the R-PAct scale. The same pattern was seen
when comparing patients using mechanical ventilation
against those with no need for ventilation.
3.2.4. Reliability
The Person Separation Index was 0.96, demonstrating
good internal consistency reliability. The test–retest reli-
ability for person location was good as well: patient loca-
tions at the ﬁrst and second assessment were nearly
always within the 95% conﬁdence intervals, reﬂecting ideal
invariance (intraclass correlation coeﬃcient 0.95) (Fig. 5).
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Fig. 4. Correlation between the R-PAct scale summed raw scores and
mobility (A) and use of ventilatory support (B) illustrating the discrim-
inatory capacity of the R-PAct scale. ICC: intraclass correlation
coeﬃcient.
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Fig. 6. Kaplan–Meier curves illustrating the proportion of Pompe
patients demonstrating clinically meaningful improvement (A) or deteri-
oration (B) during the natural disease course or during treatment with
enzyme replacement therapy, applying the concept of minimal clinically
important change (MCID) using a cut-oﬀ value of ±1.96  SE.
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Longitudinal data on the natural disease course were
available for 101 patients, while for 111 patients follow-
up data following treatment with enzyme replacement ther-
apy were evaluated. At 36 months, 21% of patients who
were being treated with enzyme replacement therapy dem-
onstrated a clinically important improvement at the indi-
vidual person-level, against 7% of patients who were not
being treated (i.e. natural disease course) (p < 0.01). By
comparison, 33% of patients who did not receive enzyme
replacement therapy demonstrated a clinically important
deterioration compared to entry, while 7% patients who
were being treated with enzyme therapy showed a clinically
meaningful deterioration (p < 0.01). Fig. 6 shows the corre-
sponding Kaplan–Meier curves.4. Discussion
We developed and validated a new, self-reported, ques-
tionnaire designed speciﬁcally for use in patients with
Pompe disease, based upon experiences from patients
N.A.M.E. van der Beek et al. / Neuromuscular Disorders 23 (2013) 256–264 263about their most important and limiting aspects in daily
life. The ﬁnal 18-items R-PAct scale was able to measure
across the spectrum of very severely to mildly aﬀected
patients without any relevant ﬂoor or ceiling eﬀects, and
showed good test–retest reliability. Furthermore, the ﬁnal
scale showed no item bias or local dependency and demon-
strated acceptable unidimensionality. The high Person Sep-
aration Index, which indicates a strong ability of the scale
to diﬀerentiate between patients with various degrees of
ability, is proof of good internal consistency reliability.
External construct validity was demonstrated by good cor-
relations with the MRC sumscore and RHS, indicating
that the R-PAct scale is capable of indirectly capturing
physical impairments leading to problems in daily and
social functioning [17]. Similar patterns between impair-
ment, disability and handicap have been reported in
patients with chronic immune-mediated neuropathies [35]
and myotonic dystrophy [20].
This study contributes to the movement from classical
test theory to modern test theory in the creation and eval-
uation of outcome measures in chronic neurological condi-
tions. Incorporating MCID techniques will help in better
understanding of the clinical relevance of changes in scores
(e.g. deﬁning responders against non-responders), rather
than concentrating on statistical signiﬁcance alone
[38,39]. Traditional responsiveness indicators do not
always provide information on the magnitude and direc-
tion of change (improvement, stable situation, or deteriora-
tion) for each individual patient. The Rasch method makes
it possible to deﬁne ‘response’ at the individual person-
level, taking into account individual standard errors chang-
ing according to patient’s ability level, and may therefore
have major implications also for future trials. Taking a
cut-oﬀ value for MCID-SE of ±1.96, the R-Pact scale
was shown to detect clinically meaningful changes over
time. This will be valuable in estimating the rate of disease
progression, determining the best moment to initiate treat-
ment, and evaluating therapeutic eﬃcacy.
In recent years, several Rasch built measures of limita-
tions in activities and participation have been constructed
for patients with neuromuscular disorders (ACTIVLIM)
[36], myotonic dystrophy type I (DM1-Activ) [20],
immune-mediated neuropathies (R-ODS) [22], and also
for children and adolescents with Pompe disease (Pompe-
PEDI) [37]. Whereas the ACTIVLIM is a generic activity
measure for patients with neuromuscular disorders, the
DM1-Activ, R-ODS and Pompe-PEDI are disease-speciﬁc
measurement instruments. The rationale for development
of yet another scale was that we expected that a measure-
ment instrument based on patients’ own experiences would
be the most appropriate to the patient group under study.
It can be argued that for diﬀerent patient groups selection
of items would be diﬀerent, or that the diﬃculty of the
selected items is diﬀerent. For example, items that are rele-
vant for patients with a proximal myopathy do not neces-
sarily apply to patients with pronounced distal skeletal
muscle weakness. In part the current measurement scaleoverlaps with the existing measurement instruments: eight
items of the ﬁnal R-PAct scale are the same as in the
DM1-Activ, and ﬁve items are shared with the ACTIV-
LIM. However, the estimated item diﬃculty diﬀers sub-
stantially between the patient groups examined.
Therefore, a disease-speciﬁc scale is more suited to estimat-
ing the impact of Pompe disease on daily life. In contrast to
the Pompe-PEDI, which was developed speciﬁcally for
children and adolescents with Pompe disease and especially
takes the domains of mobility and self-care into account,
the R-PAct scale is designed for use in patients of 16 years
or older and also addresses aspects of social participation.
We believe that the newly constructed scale gives more
insight in the disabling impact of this disorder. Neverthe-
less, for a comprehensive overview of patients’ functional-
ity it should be used complementary to clinical evaluation
methods measuring impairment, such as manual muscle
testing, quantitative muscle testing, muscle function tests
or pulmonary function testing.
Some limitations of the study need to be addressed. Ide-
ally, a sample size of approximately 250 patients is needed
to provide accurate model stability. This could only be
reached by stacking of the data. Secondly, we used the
MRC sumscore and RHS for establishing the external con-
struct validity of the newly constructed scale, which are in
fact ordinal summed scores. Recently, a revised MRC scor-
ing system was developed, which is considered a substantial
improvement in evaluating muscle strength [40]. It should
now be determined whether this modiﬁed MRC scoring
system is more appropriate for use in patients with Pompe
disease.
In conclusion, the R-PAct scale enables us to accurately
measure limitations in activities and restrictions in social
participation throughout the whole spectrum of disease
severity in patients with Pompe disease older than 16 years,
and is able to capture clinically important changes over
time. We therefore expect the R-PAct to be useful in future
studies evaluating the natural disease course or therapeutic
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